Tango Therapeutics Inc (TNGX) concluded trading on Thursday at a closing price of $4.92, with 3.39 million shares of worth about $16.7 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 58.71% during that period and on June 26, 2025 the price saw a loss of about -1.01%. Currently the company’s common shares owned by public are about 108.11M shares, out of which, 58.92M shares are available for trading.
Stock saw a price change of 2.50% in past 5 days and over the past one month there was a price change of 140.00%. Year-to-date (YTD), TNGX shares are showing a performance of -51.53% which increased to 59.22% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.03 but also hit the highest price of $12.02 during that period. The average intraday trading volume for Tango Therapeutics Inc shares is 2.47 million. The stock is currently trading 16.31% above its 20-day simple moving average (SMA20), while that difference is up 89.20% for SMA50 and it goes to 35.84% higher than SMA200.
Tango Therapeutics Inc (NASDAQ: TNGX) currently have 108.11M outstanding shares and institutions hold larger chunk of about 58.30% of that.
The stock has a current market capitalization of $533.30M and its 3Y-monthly beta is at 1.43. It has posted earnings per share of -$1.21 in the same period. It has Quick Ratio of 6.26 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNGX, volatility over the week remained 10.51% while standing at 17.47% over the month.
Stock’s fiscal year EPS is expected to drop by -13.03% while it is estimated to increase by 4.37% in next year. EPS is likely to shrink at an annualized rate of -5.61% for next 5-years, compared to annual growth of 7.47% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on July 17, 2024 offering a Buy rating for the stock and assigned a target price of $19 to it. On February 12, 2024, Piper Sandler Initiated their recommendations, while on December 08, 2023, B. Riley Securities Initiated their ratings for the stock with a price target of $16. Stock get a Buy rating from H.C. Wainwright on October 20, 2022.
